Daré Bioscience, a pioneer for women healthcare and well being has received $10 Million funding from ARPA-H’s Sprint for Women’s Health and this funding will help the company to work on the challenges related to women’s health.
DARE-HPV from Daré Bioscience is one of its unique kind of treatment for HPV(human papillomavirus) related cervical disease and has a potential to bring the positive disruption in the clinical HPV management and its effective treatment. As we know, most of the cervical cancer’s are caused by HPV and according to researches, around 4,000 women are dying from cancer while appx. 100,000 are still being treated for cervical precancer. Since, the cervical cancer requires a surgery to treat so most of the medics keeps a close monitoring until it reaches a later stage and removes the part of cervix that is infected but this can be a complex one and might lead to death.
With DARE-HPV, doctors can treat the cervical disease at an early stage as well as at a later stage making it one of the versatile treatment solution.
Sabrina Johnson is the President and CEO of Daré Bioscience and she founded this company in the year of 2015 with an aim to improve the lives of women’s across the world. Daré is a biopharmaceutical company and is on a mission to market healthcare and medical solutions for women’s across the globe.
Leave a Reply